In evaluating the NCDB, we endeavored to expand upon the aforementioned NIH WT GIST Clinic and SEER database analyses by focusing on a national cohort of patients with GIST with documented wild-type KIT and PDGFRA. We aimed to determine the clinicopathologic features of this tumor type and identify the factors that influenced overall survival in order to provide a more complete understanding upon which management recommendations could be based for this rare tumor. This evidence concerns the gene PDGFRA and gastrointestinal stromal tumor.